Clinical trial to assess tolerability and subrogate efficacy effects of an abbreviated schedule with house dust mites mixture subcutaneous immunotherapy

Eur Ann Allergy Clin Immunol. 2021 Mar;53(2):67-74. doi: 10.23822/EurAnnACI.1764-1489.140. Epub 2021 Mar 1.

Abstract

Objective. To evaluate the tolerability and efficacy of Dermatophagoides pteronyssinus/Dermatophagoides farinae mixture subcutaneous immunotherapy (SCIT). Methods. Patients received an abbreviated build-up schedule. The aims were: number, percentage, and severity of adverse reactions. Secondary outcomes included: changes in immunoglobulin titers and changes in dose-response skin prick tests. Results. Out of 289 administrations, 17% elicited any clinically relevant adverse reaction. Most of them were local reactions (LR) (9.4%) and the rest (7.6%) were systemic. Significant increases in sIgG and sIgG4 were detected in serum samples. Cutaneous reactivity decreased significantly. Conclusions. SCIT with house dust mites mixture of ROXALL Medicina España S.A. seems to have an acceptable tolerability profile, induces blocking IgG and decreases skin reactivity.

Keywords: Abbreviated schedule; DPT/DF mixture; house dust mites; rhinoconjunctivitis; subcutaneous immunotherapy.

MeSH terms

  • Adult
  • Allergens
  • Animals
  • Antigens, Dermatophagoides
  • Female
  • Humans
  • Immunotherapy / methods*
  • Male
  • Mites / immunology*
  • Pyroglyphidae / immunology*
  • Skin Tests / methods*
  • Spain

Substances

  • Allergens
  • Antigens, Dermatophagoides